Sei Investments CO Axogen, Inc. Transaction History

Sei Investments CO

$75.3 Billion
Q4 2024

A detailed history of Sei Investments CO transactions in Axogen, Inc. stock. As of the latest transaction made, Sei Investments CO holds 11,384 shares of AXGN stock, worth $201,724. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,384

Holding current value

$201,724

% of portfolio

0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 11, 2025	BUY	$12.47 - $17.19 $141,958 - $195,690	11,384 New	11,384 $187,000
Q2 2020 Aug 11, 2020	SELL	$7.35 - $10.81 $14,589 - $21,457	-1,985 Reduced 6.49%	28,586 $511,000
Q1 2020 May 14, 2020	BUY	$8.38 - $17.34 $16,634 - $34,419	1,985 Added 6.94%	30,571 $318,000
Q4 2019 Feb 06, 2020	SELL	$11.18 - $18.6 $32,231 - $53,623	-2,883 Reduced 9.16%	28,586 $511,000
Q3 2019 Nov 12, 2019	SELL	$12.09 - $20.46 $268,567 - $454,498	-22,214 Reduced 41.38%	31,469 $393,000
Q2 2019 Aug 14, 2019	BUY	$18.5 - $25.47 $740,055 - $1.02 Million	40,003 Added 292.42%	53,683 $1 Million
Q1 2019 May 15, 2019	BUY	$14.62 - $22.13 $198,568 - $300,569	13,582 Added 13859.18%	13,680 $288,000
Q3 2018 Nov 08, 2018	SELL	$34.05 - $55.9 $571,529 - $938,281	-16,785 Reduced 99.42%	98 $4,000
Q2 2018 Aug 03, 2018	BUY	$36.15 - $52.5 $610,320 - $886,357	16,883 New	16,883 $848,000

Others Institutions Holding AXGN

# of Institutions

176

Shares Held

36.6M

Call Options Held

230K

Put Options Held

400

First Light Asset Management, LLC Edina, MN

4.09M
Shares

$72.5 Million
5.0% of portfolio
Black Rock Inc. New York, NY

3.25M
Shares

$57.6 Million
0.0% of portfolio
Soleus Capital Management, L.P. Greenwich, CT

3.01M
Shares

$53.3 Million
3.58% of portfolio
Morgan Stanley New York, NY

2.9M
Shares

$51.4 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

2.43M
Shares

$43 Million
0.0% of portfolio

View Full List

About Axogen, Inc.

Ticker AXGN
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 42,283,700
Market Cap $749M
Description
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...

More about AXGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

News

Stay updated on Sei Investments CO with notifications on news.

Account